EQT Future, EQT's new impact-driven longer-hold investment strategy, and ATHOS, alongside other co-investors (the "Consortium"), have today announced an investment in SHL Medical ("the Company"), a world-leading provider of drug delivery solutions. The Consortium will acquire a minority share of the Company from EQT's Equity fund VIII, which will exit the Company. Roger Samuelsson, the Company's founder, will remain the majority shareholder.

Headquartered in Switzerland, SHL Medical has a global presence with offices and operations in Europe, Asia, and the United States, employing more than 5,000 people worldwide. SHL Medical is a pioneer in medical autoinjectors, which allow patients to safely self-administer medications at home while reducing the burden on healthcare systemsEQT first partnered with SHL Medical in January 2020 through its EQT VIII fund. SHL Medical is all of this and more.

https://www.shl-medical.com/

Eqt Future And Athos, Alongside Other Co-Investors, Invest In Shl Medical, A World-Leading Provider Of Advanced Drug Delivery Solutions

Description

Company Information

Related People

Eqt Future And Athos, Alongside Other Co-Investors, Invest In Shl Medical, A World-Leading Provider Of Advanced Drug Delivery Solutions

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Company Information